Second generation sequencing of the mesothelioma tumor genome
- PMID: 20485525
- PMCID: PMC2869344
- DOI: 10.1371/journal.pone.0010612
Second generation sequencing of the mesothelioma tumor genome
Abstract
The current paradigm for elucidating the molecular etiology of cancers relies on the interrogation of small numbers of genes, which limits the scope of investigation. Emerging second-generation massively parallel DNA sequencing technologies have enabled more precise definition of the cancer genome on a global scale. We examined the genome of a human primary malignant pleural mesothelioma (MPM) tumor and matched normal tissue by using a combination of sequencing-by-synthesis and pyrosequencing methodologies to a 9.6X depth of coverage. Read density analysis uncovered significant aneuploidy and numerous rearrangements. Method-dependent informatics rules, which combined the results of different sequencing platforms, were developed to identify and validate candidate mutations of multiple types. Many more tumor-specific rearrangements than point mutations were uncovered at this depth of sequencing, resulting in novel, large-scale, inter- and intra-chromosomal deletions, inversions, and translocations. Nearly all candidate point mutations appeared to be previously unknown SNPs. Thirty tumor-specific fusions/translocations were independently validated with PCR and Sanger sequencing. Of these, 15 represented disrupted gene-encoding regions, including kinases, transcription factors, and growth factors. One large deletion in DPP10 resulted in altered transcription and expression of DPP10 transcripts in a set of 53 additional MPM tumors correlated with survival. Additionally, three point mutations were observed in the coding regions of NKX6-2, a transcription regulator, and NFRKB, a DNA-binding protein involved in modulating NFKB1. Several regions containing genes such as PCBD2 and DHFR, which are involved in growth factor signaling and nucleotide synthesis, respectively, were selectively amplified in the tumor. Second-generation sequencing uncovered all types of mutations in this MPM tumor, with DNA rearrangements representing the dominant type.
Conflict of interest statement
Figures
Similar articles
-
Transcriptome sequencing of malignant pleural mesothelioma tumors.Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3521-6. doi: 10.1073/pnas.0712399105. Epub 2008 Feb 26. Proc Natl Acad Sci U S A. 2008. PMID: 18303113 Free PMC article.
-
Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.BMC Med Genet. 2009 Dec 31;10:149. doi: 10.1186/1471-2350-10-149. BMC Med Genet. 2009. PMID: 20043850 Free PMC article.
-
Next generation mapping reveals novel large genomic rearrangements in prostate cancer.Oncotarget. 2017 Apr 4;8(14):23588-23602. doi: 10.18632/oncotarget.15802. Oncotarget. 2017. PMID: 28423598 Free PMC article.
-
Molecular changes in mesothelioma with an impact on prognosis and treatment.Arch Pathol Lab Med. 2012 Mar;136(3):277-93. doi: 10.5858/arpa.2011-0215-RA. Arch Pathol Lab Med. 2012. PMID: 22372904 Review.
-
[Molecular heterogeneity of malignant pleural mesotheliomas].Bull Cancer. 2018 Jan;105(1):35-45. doi: 10.1016/j.bulcan.2017.11.007. Epub 2017 Dec 23. Bull Cancer. 2018. PMID: 29277245 Review. French.
Cited by
-
Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion.Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1128-36. doi: 10.1073/pnas.1110574108. Epub 2011 Nov 7. Proc Natl Acad Sci U S A. 2011. PMID: 22065754 Free PMC article.
-
Genomics and Epigenetics of Malignant Mesothelioma.High Throughput. 2018 Jul 27;7(3):20. doi: 10.3390/ht7030020. High Throughput. 2018. PMID: 30060501 Free PMC article. Review.
-
New DNA sequencing technologies open a promising era for cancer research and treatment.Clin Transl Oncol. 2011 May;13(5):301-6. doi: 10.1007/s12094-011-0658-1. Clin Transl Oncol. 2011. PMID: 21596657 Review.
-
The somatic autosomal mutation matrix in cancer genomes.Hum Genet. 2015 Aug;134(8):851-64. doi: 10.1007/s00439-015-1566-1. Epub 2015 May 23. Hum Genet. 2015. PMID: 26001532 Free PMC article.
-
Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma.Front Oncol. 2021 Dec 8;11:789244. doi: 10.3389/fonc.2021.789244. eCollection 2021. Front Oncol. 2021. PMID: 34956905 Free PMC article.
References
-
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. - PubMed
-
- Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1(2):175–176. - PubMed
-
- Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000;1(4):313–326. - PubMed
-
- Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am. 2005;19(6):1117–1136, vii. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous